A novel 11β-hydroxysteroid dehydrogenase type1 inhibitor CNX-010-49 improves hyperglycemia, lipid profile and reduces body weight in diet induced obese C57B6/J mice with a potential to provide cardio protective benefits

BMC Clinical Pharmacology

Baggavalli P Somesh¹  Madanahalli R Jagannath¹  Marikunte V Venkataranganna¹  Yoganand Moolemath¹  Mammen O Anup¹  ManojKumar Sadasivuni¹  Shivakumar Pratibha¹  Aralakuppe S Gopala¹  Baisani S Naveen Kumar¹  Gundalmandikal V Balamurali¹  Chandrashekaran Harish¹  Venkategowda Sunil¹  Mudigere N Lakshmi¹  Venkatesh Satish Kumar¹  Nitya Shree¹  Jaideep Singh¹  KrishnaReddy Harsha¹  Anilkumar Dandu¹  Tharappel M Anil¹ 

[1]Connexios Life Sciences Pvt Ltd, Bangalore, India

关键词: Cardiovascular risks;    Type 2 Diabetes;    Adipogenesis and Body weight;    Triglycerides;    Insulin sensitivity;    Glucose;    CNX-010-49;    11β-HSD1;   

Others  :  1084871
DOI  :  10.1186/2050-6511-15-43

 received in 2014-02-07, accepted in 2014-07-29,  发布年份 2014

【 摘 要 】

Background

11ß–hydroxysteroid dehydrogenase type1 (11β-HSD1) converts inactive glucocorticoids to active glucocorticoids which, in excess, leads to development of the various risk factors of the metabolic syndrome. Recent studies clearly suggest that both increased expression and activity of 11β-HSD1 in metabolically active tissues such as liver, muscle and adipose are implicated in tissue specific dysregulation which collectively contribute to the whole body pathology seen in metabolic syndrome. In the present study we have evaluated CNX-010-49, a highly potent, selective and ‘pan tissue’ acting 11β-HSD1 inhibitor, for its potential to modulate multiple risk factors of the metabolic syndrome.

Methods

Male C57B6/J mice on high fat diet (DIO mice) were orally dosed with CNX-010-49 (30 mg/kg twice daily; n = 8) or vehicle for 10 weeks. Fasting glucose, triglycerides, glycerol, free fatty acids, body weight and feed intake were measured at selected time points. At the end of the treatment an OGTT and subsequently organ histology was performed. In vitro, CNX-010-49 was evaluated in 3T3-L1 preadipocytes to assess impact on adipocytes differentiation, hypertrophy and lipolysis whereas in fully differentiated C2C12 cells and in primary mouse hepatocytes to assess the impact on glucose metabolism and hepatic glucose output respectively.

Results

CNX-010-49 a highly potent and selective pan tissue acting 11β-HSD1 inhibitor (EC₅₀ = 6 nM) significantly inhibits glucocorticoids and isoproterenol mediated lipolysis in mature 3T3-L1 adipocytes, improves muscle glucose oxidation, reduces proteolysis and enhances mitochondrial biogenesis. Also a significant inhibition of gluconeogenesis in primary mouse hepatocytes was observed. The treatment with CNX-010-49 resulted in a significant decrease in fasting glucose, improved insulin sensitivity and glucose tolerance. Treatment also resulted in a significant decrease in serum triglycerides levels and a complete inhibition of body weight gain without affecting feed consumption. A significant reduction in the serum biomarkers like Plasminogen activator inhibitor-1 (PAI-1), interleukin 6 (IL-6) and Fetuin-A with CNX-010-49 treatment was observed indicating a potential to modulate processes implicated in cardiovascular benefits.

Conclusions

These results indicate that inhibition of 11β-HSD1 with CNX-010-49 can give a potential benefit in the management of metabolic dysregulations that are seen in type 2 diabetes.

【 授权许可】

   
2014 Anil et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

【 参考文献 】

• [1]Hadoke PWF, Iqbal J, Walker BR: Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease. Br J Pharmacol 2009, 156(5):689-712.
• [2]Friedman TC, Mastorakos G, Newman TD, Mullen NM, Horton EG, Costello R, Papadopoulos NM, Chrousos GP: Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM. Endocr J 1996, 43(6):645-655.
• [3]Stewart PM, Krozowski ZS: 11 beta-Hydroxysteroid dehydrogenase. Vitam Horm 1999, 57:249-324.
• [4]Ricketts ML, Verhaeg JM, Bujalska I, Howie AJ, Rainey WE, Stewart PM: Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab 1998, 83:1325-1335.
• [5]Whorwood CB, Mason JI, Ricketts ML, Howie AJ, Stewart PM: Detection of human 11 beta-hydroxysteroid dehydrogenase isoforms using reverse-transcriptase-polymerase chain reaction and localization of the type 2 isoform to renal collecting ducts. Mol Cell Endocrinol 1995, 110(1–2):R7-R12.
• [6]Dzyakanchuk AA, Balázs Z, Nashev LG, Amrein KE, Odermatt A: 11beta-Hydroxysteroid dehydrogenase 1 reductase activity is dependent on a high ratio of NADPH/NADP(+) and is stimulated by extracellular glucose. Mol Cell Endocrinol 2009, 301(1–2):137-141.
• [7]Hughes KA, Manolopoulos KN, Iqbal J, Cruden NL, Stimson RH, Reynolds RM, Newby DE, Andrew R, Karpe F, Walker BR: Recycling between cortisol and cortisone in human splanchnic, subcutaneous adipose, and skeletal muscle tissues in vivo. Diabetes 2012, 61(6):1357-1364.
• [8]Shpilberg Y, Beaudry JL, D’Souza A, Campbell JE, Peckett A, Riddell MC: A rodent model of rapid-onset diabetes induced by glucocorticoids and high-fat feeding. Dis Model Mech 2012, 5(5):671-680.
• [9]Cusin I, Rouru J, Rohner-Jeanrenaud F: Intracerebroventricular glucocorticoid infusion in normal rats: induction of parasympathetic-mediated obesity and insulin resistance. Obes Res 2001, 9(7):401-406.
• [10]Zakrzewska KE, Cusin I, Stricker-Krongrad A, Boss O, Ricquier D, Jeanrenaud B, Rohner-Jeanrenaud F: Induction of obesity and hyperleptinemia by central glucocorticoid infusion in the rat. Diabetes 1999, 48(2):365-370.
• [11]Moriscot A, Rabelo R, Bianco AC: Corticosterone inhibits uncoupling protein gene expression in brown adipose tissue. Am J Physiol 1993, 265(1 Pt 1):E81-E87.
• [12]Strack AM, Bradbury MJ, Dallman MF: Corticosterone decreases nonshivering thermogenesis and increases lipid storage in brown adipose tissue. Am J Physiol 1995, 268(1 Pt 2):R183-R191.
• [13]Rask E, Olsson T, Söderberg S, Andrew R, Livingstone DE, Johnson O, Walker BR: Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001, 86(3):1418-1421.
• [14]Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CRW, Seckl JR, Mullins JJ: 11{beta}-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. PNAS 1997, 94(26):14924-14929.
• [15]Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS: A transgenic model of visceral obesity and the metabolic syndrome. Science 2001, 294(5549):2166-2170.
• [16]Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, Shinyama H, Sharp MG, Fleming S, Mullins JJ, Seckl JR, Flier JS: Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003, 112(1):83-90.
• [17]Rask E, Walker BR, Söderberg S, Livingstone DE, Eliasson M, Johnson O, Andrew R, Olsson T, Clin J: Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 2002, 87(7):3330-3336.
• [18]Paulmyer-Lacroix O, Bouliu S, Oliver C, Alessi M-C, Grino M: Expression of the mRNA coding for 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 2002, 87(6):2701-2705.
• [19]Livingstone DE1, Jones GC, Smith K, Jamieson PM, Andrew R, Kenyon CJ, Walker BR: Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 2000, 141(2):560-563.
• [20]Livingstone DE, Kenyon CJ, Walker BR: Mechanisms of dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 in obese Zucker rats. J Endocrinol 2000, 167:533-539.
• [21]Harno E, Cottrell EC, Keevil BG, DeSchoolmeester J, Bohlooly-Y M, Andersén H, Turnbull AV, Leighton B, White A: 11-Dehydrocorticosterone causes metabolic syndrome, which is prevented when 11β-HSD1 is knocked out in livers of male mice. Endocrinology 2013, 154(10):3599-3609.
• [22]Lavery GG, Zielinska AE, Gathercole LL, Hughes B, Semjonous N, Guest P, Saqib K, Sherlock M, Reynolds G, Morgan SA, Tomlinson JW, Walker EA, Rabbitt EH, Stewart PM: Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11β-hydroxysteroid dehydrogenase type 1. Endocrinology 2012, 153(7):3236-3248.
• [23]Morgan SA, Sherlock M, Gathercole LL, Lavery GG, Lenaghan C, Bujalska IJ, Laber D, Yu A, Convey G, Mayers R, Hegyi K, Sethi JK, Stewart PM, Smith DM, Tomlinson JW: 11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes 2009, 58(11):2506-2515.
• [24]Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, Klingstrom G, Larsson C, Forsgren M, Ashkzari M, Nilsson CE, Fiedler M, Bergqvist E, Ohman B, Bjorkstrand E, Abrahmsen LB: Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 2003, 144(11):4755-4762.
• [25]Alberts P, Engblom L, Edling N, Forsgren M, Klingstrom G, Larsson C, Ronquist-Nii Y, Ohman B, Abrahmsen L: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002, 45(11):1528-1532.
• [26]Barf T, Vallgarda J, Emond R, Haggstrom C, Kurz G, Nygren A, Larwood V, Mosialou E, Axelsson K, Olsson R, Engblom L, Edling N, Ronquist-Nii Y, Ohman B, Alberts P, Abrahmsen L: Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs: discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1. J Med Chem 2002, 45(18):3813-3815.
• [27]Bhat BG, Hosea N, Fanjul A, Herrera J, Chapman J, Thalacker F, Stewart PM, Rejto PA: Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4′-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. J Pharmacol Exp Ther 2008, 324(1):299-305.
• [28]Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, Le Grand CB, Li Z, Metzger JM, Mundt SS, Noonan H, Nunes CN, Olson SH, Pikounis B, Ren N, Robertson N, Schaeffer JM, Shah K, Springer MS, Strack AM, Strowski M, Wu K, Wu T, Xiao J, Zhang BB, Wright SD, Thieringer R: 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 2005, 202(4):517-527.
• [29]Sundbom M, Kaiser C, Björkstrand E, Castro VM, Larsson C, Selén G, Nyhem CS, James SR: Inhibition of 11betaHSD1 with the S-phenylethylaminothiazolone BVT116429 increases adiponectin concentrations and improves glucose homeostasis in diabetic KKAy mice. BMC Pharmaco 2008. 10.1186/1471-2210-8-3
• [30]Taylor A, Irwin N, McKillop AM, Flatt PR, Gault VA: Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity. Biol Chem 2008, 389(4):441-445.
• [31]Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, Yao W, Hollis G, Flores R, Levy R, Williams WV, Seckl JR, Huber R: The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 2010, 33(7):1516-1522.
• [32]Feig PU, Shah S, Hermanowski-Vosatka A, Plotkin D, Springer MS, Donahue S, Thach C, Klein EJ, Lai E, Kaufman KD: Effects of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab 2011, 13(6):498-504.
• [33]Seglenin PO: Preparation of isolated rat liver cells. Methods Cell Biol 1976, 13:29-83.
• [34]Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG: Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 2010, 8(6):e1000412.
• [35]Ohshima K, Shargill NS, Chan TM, Bray GA: Adrenalectomy reverses insulin resistance in muscle from obese (ob/ob) mice. Am J Physiol 1984, 246:E193-E197.
• [36]Okada S, York DA, Bray GA: Mifepristone (RU 486), a blocker type II glucocorticoid and progestin receptors, reverses a dietary form obesity. Am J Physiol 1992, 262:R1106-R1110.
• [37]Shimomura Y, Bray GA, Lee M: Adrenalectomy and steroid treatment in obese (ob/ob) and diabetic (db/db) mice. Horm Metab Res 1987, 19:295-299.
• [38]Chrousos GP: Is 11beta-hydroxysteroid dehydrogenase type 1 a good therapeutic target for blockade of glucocorticoid actions? Proc Natl Acad Sci U S A 2004, 101(17):6329-6330.
• [39]Fan Z, Du H, Zhang M, Meng Z, Chen L, Liu Y: Direct regulation of glucose and not insulin on hepatic hexose-6-phosphate dehydrogenase and 11β-hydroxysteroid dehydrogenase type 1. Mol Cell Endocrinol 2011, 333(1):62-69.
• [40]Ma R, Zhang W, Tang K, Zhang H, Zhang Y, Li D, Li Y, Xu P, Luo S, Cai W, Ji T, Katirai F, Ye D, Huang B: Switch of glycolysis to gluconeogenesis by dexamethasone for treatment of hepatocarcinoma. Nat Commun 2013, 4:2508.
• [41]Wang X, Hu Z, Hu J, Du J, Mitch WE: Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology 2006, 147(9):4160-4168.
• [42]Salehzadeh F, Al-Khalili L, Kulkarni SS, Wang M, Lönnqvist F, Krook A: Glucocorticoid-mediated effects on metabolism are reversed by targeting 11 beta hydroxysteroid dehydrogenase type 1 in human skeletal muscle. Diabetes Metab Res Rev 2009, 25(3):250-258.
• [43]Connaughton S, Chowdhury F, Attia RR, Song S, Zhang Y, Elam MB, Cook GA, Park EA: Regulation of pyruvate dehydrogenase kinase isoform 4 (PDK4) gene expression by glucocorticoids and insulin. Mol Cell Endocrinol 2010, 315(1–2):159-167.
• [44]Biedasek K, Andres J, Mai K, Adams S, Spuler S, Fielitz J, Spranger J: Skeletal muscle 11beta-HSD1 controls glucocorticoid-induced proteolysis and expression of E3 ubiquitin ligases atrogin-1 and MuRF-1. PLoS One 2011, 6(1):e16674.
• [45]Dolinsky VW, Douglas DN, Lehner R, Vance DE: Regulation of the enzymes of hepatic microsomal triacylglycerol lipolysis and re-esterification by the glucocorticoid dexamethasone. Biochem J 2004, 378(Pt 3):967-974.
• [46]Mantha L, Palacios E, Deshaies Y: Modulation of triglyceride metabolism by glucocorticoids in diet-induced obesity. Am J Physiol 1999, 277(2 Pt 2):R455-R464.
• [47]Koonen DP, Jacobs RL, Febbraio M, Young ME, Soltys CL, Ong H, Vance DE, Dyck JR: Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes 2007, 56(12):2863-2871.
• [48]Hermanowski-Vosatka A, Gerhold D, Mundt SS, Loving VA, Lu M, Chen Y, Elbrecht A, Wu M, Doebber T, Kelly L, Milot D, Guo Q, Wang PR, Ippolito M, Chao YS, Wright SD, Thieringer R: PPARalpha agonists reduce 11beta-hydroxysteroid dehydrogenase type 1 in the liver. Biochem Biophys Res Commun 2000, 279(2):330-336.
• [49]Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR, Mullins JJ: 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci U S A 1997, 94(26):14924-14929.
• [50]Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, Flier JS, Mullins JJ, Seckl JR: Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004, 53(4):931-938.
• [51]Viengchareun S1, Penfornis P, Zennaro MC, Lombès M: Mineralocorticoid and glucocorticoid receptors inhibit UCP expression and function in brown adipocytes. Am J Physiol Endocrinol Metab 2001, 280(4):E640-E649.
• [52]Seale P, Kajimura S, Yang W, Chin S, Rohas LM, Uldry M, Tavernier G, Langin D, Spiegelman BM: Transcriptional control of brown fat determination by PRDM16. Cell Metab 2007, 6(1):38-54.
• [53]Ricquier D: Respiration uncoupling and metabolism in the control of energy expenditure. Proc Nutr Soc 2005, 64(1):47-52.
• [54]Maréchal C, Schlieper G, Nguyen P, Krüger T, Coche E, Robert A, Floege J, Goffin E, Jadoul M, Devuyst O: Serum fetuin-A levels are associated with vascular calcifications and predict cardiovascular events in renal transplant recipients. Clin J Am Soc Nephrol 2011, 6(5):974-985.
• [55]Westenfeld R, Schäfer C, Smeets R, Brandenburg VM, Floege J, Ketteler M, Jahnen-Dechent W: Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice. Nephrol Dial Transplant 2007, 22(6):1537-1546.
• [56]Kirton JP, Wilkinson FL, Canfield AE, Alexander MY: Dexamethasone downregulates calcification-inhibitor molecules and accelerates osteogenic differentiation of vascular pericytes: implications for vascular calcification. Circ Res 2006, 98(10):1264-1272.
• [57]Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I: Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997, 46(5):860-867.
• [58]Morange PE, Aubert J, Peiretti F, Lijnen HR, Vague P, Verdier M, Négrel R, Juhan-Vague I, Alessi MC: Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes 1999, 48(4):890-895.
• [59]Willerson JT, Ridker PM: Inflammation as a cardiovascular risk factor. Circulation 2004, 109(21 Suppl 1):II2-II10.